PATENT LINKAGE: ITS PRESENCE, BALANCING PATENT PROTECTION AND GENERIC ENTRY
Patent linkage is a system that connects the approval of generic drugs with the patent status of the corresponding originator (brand-name) drugs. This linkage is designed to protect the intellectual property rights of patent holders and to ensure a balance between innovation and competition in the pharmaceutical industry. Different countries may have varying approaches to patent linkage, and some may not have a formal system in place. Here's a brief overview of patent linkage systems in different countries:
1. United States:In the U.S., the Hatch-Waxman Act established a patent linkage system. Generic drug manufacturers must certify their position regarding relevant patents before receiving approval from the U.S. Food and Drug Administration (FDA) for their generic versions. The patent holder can then initiate a patent infringement lawsuit, triggering an automatic stay of FDA approval for a specified period.
2. European Union:The European Union (EU) does not have a formal patent linkage system comparable to that of the United States. Instead, the EU relies on the Supplementary Protection Certificate (SPC) system, which provides additional protection for patented medicinal products.
3. Canada:Canada has a patent linkage system that requires generic drug manufacturers to address the patent status of the corresponding brand-name drugs when seeking regulatory approval. The system aims to balance the interests of innovators and generic manufacturers while facilitating early resolution of patent disputes.
4. India:India does not have a formal patent linkage system. However, the country has provisions in its patent law that allow patent holders to seek injunctions against the marketing of infringing products, including generic versions. The Indian legal system does not automatically stay regulatory approvals based on patent status.
5. South Korea:South Korea has a patent linkage system that requires generic drug manufacturers to provide notice to patent holders when seeking regulatory approval for their products. The patent holder can then seek an injunction to prevent the approval of the generic drug if there are patent concerns.
6. Australia:Australia has a patent linkage system that requires generic manufacturers to notify patent holders when seeking marketing approval. Patent holders can then seek an injunction to delay the approval of generic drugs.
7. China:China has implemented a patent linkage system as part of its efforts to strengthen intellectual property protection. The system allows patent holders to file litigation to prevent the marketing of generic drugs that may infringe on their patents.
It's important to note that the specifics of patent linkage systems can vary, and changes in legislation may occur over time. Additionally, not all countries have formal patent linkage systems, and alternative mechanisms may be in place to address patent disputes related to generic drug approvals.Thanks
DS IP services